Most recent by Jai N. Patel, PharmD, BCOP, CPP
Improving dose optimization in oncology: The sotorasib example
Until the last decade, efforts to develop a therapy that successfully targeted the KRAS mutation had been futile.
Pharmacogenetic testing may improve outcomes for patients with depression
COVID-19 has caused major physical and psychological harm for millions of Americans.
Cancer drugs’ targeted, anti-inflammatory effects support repurposing for COVID-19
Since the COVID-19 pandemic began, researchers around the world have joined the effort to develop a vaccine and test potential treatments.
Cancer drugs’ targeted, anti-inflammatory effects support repurposing for COVID-19
Since the COVID-19 pandemic began, researchers around the world have joined the effort to develop a vaccine and test potential treatments.
Polypharmacy management among older adults with cancer requires multipronged approach
Management of polypharmacy — the concurrent use of five or more medications — is a major challenge for clinicians who care for older adults.
Immunotherapy effective for many patients ineligible for registration trials, but caution necessary
One of the hot topics at this year’s ASCO Annual Meeting was broadening eligibility criteria to increase clinical trial access and enrollment.
Risk-based approach must guide VTE prophylaxis for ambulatory patients with cancer
Individuals with cancer are more than four times as likely as those in the general population to develop venous thromboembolism.
Urgent action necessary to address opioid drug shortage
The frequency of drug shortages in the United States is rapidly increasing.
Differences in pharmacology, toxicities key to clinical use of PARP inhibitors
The development of targeted treatments has dramatically improved outcomes for patients with several types of cancer.
Effective pharmacological management of depression ‘imperative’ for patients with cancer
Major depression is a significant comorbidity in cancer, with prevalence estimated at 15% to 20%.